X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gemtuzumab ozogamicin (880) 880
humans (640) 640
index medicus (519) 519
hematology (404) 404
oncology (384) 384
acute myeloid-leukemia (351) 351
acute myeloid leukemia (264) 264
chemotherapy (234) 234
cancer (230) 230
female (201) 201
leukemia, myeloid, acute - drug therapy (200) 200
acute myelogenous leukemia (190) 190
male (187) 187
antineoplastic agents - therapeutic use (180) 180
aged (177) 177
antibodies, monoclonal - therapeutic use (161) 161
middle aged (159) 159
leukemia (152) 152
animals (150) 150
therapy (149) 149
treatment outcome (140) 140
older patients (137) 137
antibodies, monoclonal, humanized (132) 132
adult (126) 126
antineoplastic combined chemotherapy protocols - therapeutic use (119) 119
aml (116) 116
pharmacology & pharmacy (109) 109
prognosis (107) 107
leukemia, myeloid, acute - therapy (99) 99
aminoglycosides - therapeutic use (98) 98
immunotherapy (98) 98
stem-cell transplantation (98) 98
acute promyelocytic leukemia (89) 89
transplantation (87) 87
monoclonal antibodies (86) 86
adult patients (85) 85
care and treatment (85) 85
induction chemotherapy (83) 83
efficacy (82) 82
medicine & public health (81) 81
aminoglycosides - administration & dosage (79) 79
survival (78) 78
cd33 (77) 77
monoclonal-antibody (77) 77
recurrence (76) 76
remission induction (76) 76
sialic acid binding ig-like lectin 3 (76) 76
minimal residual disease (74) 74
review (74) 74
aged, 80 and over (71) 71
leukemia, myeloid, acute - mortality (71) 71
leukemia, myeloid, acute - pathology (71) 71
cytarabine (70) 70
hemic and lymphatic diseases (70) 70
phase-i (70) 70
trans-retinoic acid (69) 69
antibodies, monoclonal - administration & dosage (68) 68
research (67) 67
clinical trials as topic (66) 66
health aspects (66) 66
mylotarg (66) 66
mice (65) 65
antineoplastic agents - pharmacology (64) 64
medicine, research & experimental (63) 63
stem cells (63) 63
antineoplastic agents - administration & dosage (62) 62
antibodies (61) 61
leukemia, myeloid, acute - genetics (61) 61
relapse (61) 61
adolescent (60) 60
elderly-patients (60) 60
antibodies, monoclonal - adverse effects (59) 59
antibodies, monoclonal, humanized - therapeutic use (58) 58
cell line, tumor (57) 57
acute disease (56) 56
immunoconjugates - therapeutic use (56) 56
expression (55) 55
leukemia, myeloid, acute - immunology (55) 55
cytarabine - administration & dosage (54) 54
acute lymphoblastic-leukemia (53) 53
article (53) 53
hematology, oncology and palliative medicine (52) 52
immunology (52) 52
in-vitro (52) 52
children (51) 51
induction (50) 50
open-label (50) 50
aminoglycosides - adverse effects (49) 49
neoplasms - drug therapy (49) 49
calicheamicin (48) 48
clinical trials (48) 48
phase-ii (48) 48
young adult (48) 48
antineoplastic agents (47) 47
antineoplastic agents - adverse effects (47) 47
child (47) 47
survival rate (47) 47
intensive chemotherapy (46) 46
targeted therapy (46) 46
drug therapy (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (980) 980
French (8) 8
German (8) 8
Polish (2) 2
Hungarian (1) 1
Italian (1) 1
Japanese (1) 1
Portuguese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Journal Article
Cancer, ISSN 0008-543X, 10/2005, Volume 104, Issue 7, pp. 1442 - 1452
Journal Article
Cancer, ISSN 0008-543X, 07/2001, Volume 92, Issue 2, pp. 406 - 413
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 21, pp. 2100 - 2101
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2018, Volume 24, Issue 14, pp. 3242 - 3246
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a... 
SURVIVAL | TRIALS | INDUCTION | PHASE-3 | EFFICACY | ONCOLOGY | Thrombocytopenia | Regulatory agencies | Calicheamicin | Toxicity | Myeloid leukemia | Leukemia | Pharmacology | FDA approval | Hemorrhage | Patients | Survival | Veno-occlusive disease | Confidence intervals | Randomization | Cytarabine | Daunorubicin | Immunogenicity | Adults | Pharmacokinetics | Gemtuzumab ozogamicin | Acute myeloid leukemia | Cancer
Journal Article
European Journal of Haematology, ISSN 0902-4441, 05/2017, Volume 98, Issue 5, pp. 425 - 434
Despite an improved understanding of disease biology and the use of multi‐agent chemotherapy, the long‐term survival of adults with B‐cell acute lymphoblastic... 
relapsed acute lymphoblastic leukemia | inotuzumab ozogamicin | GEMTUZUMAB OZOGAMICIN | CD22 MONOCLONAL-ANTIBODY | ANTIBODY-TARGETED CHEMOTHERAPY | PROGNOSTIC-FACTORS | ACUTE LYMPHOCYTIC-LEUKEMIA | CD22-TARGETED IMMUNOCONJUGATE | NON-HODGKIN-LYMPHOMA | SALVAGE THERAPY | HEMATOLOGY | CLINICAL ACTIVITY | PHASE-I | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - epidemiology | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Humans | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Molecular Targeted Therapy | Lymphoma, Non-Hodgkin - pathology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Monoclonal, Humanized - pharmacology | Antineoplastic Agents - pharmacology | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | CD22 antigen | Endocytosis | Chemotherapy | Acute lymphatic leukemia | Cell survival | Immunoconjugates | Lymphocytes B | Leukemia | Lymphatic leukemia
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 4, pp. 698 - 704
Abstract Myeloablative conditioning and allogeneic hematopoietic stem cell transplant (alloHSCT) in children with acute myeloid leukemia (AML) in first... 
Hematology, Oncology and Palliative Medicine | Reduced-intensity conditioning | Allogeneic stem cell transplantation | Gemtuzumab ozogamicin | Pediatric AML | Immunotherapy | ONCOLOGY-GROUP | EVENT-FREE SURVIVAL | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | VERSUS-HOST-DISEASE | NONMALIGNANT DISEASES | TRANSPLANTATION | PEDIATRIC RECIPIENTS | UMBILICAL-CORD BLOOD | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | MYCOPHENOLATE-MOFETIL | CLINICAL-SIGNIFICANCE | Myeloablative Agonists - therapeutic use | Immunotherapy - methods | Consolidation Chemotherapy - methods | Humans | Immunosuppressive Agents - therapeutic use | Sialic Acid Binding Ig-like Lectin 3 - immunology | Child, Preschool | Male | Leukemia, Myeloid, Acute - immunology | Graft vs Host Disease - immunology | Transplantation, Homologous | Young Adult | Graft vs Host Disease - mortality | Antilymphocyte Serum - therapeutic use | Female | Unrelated Donors | Transplantation Conditioning - methods | Child | Leukemia, Myeloid, Acute - therapy | Siblings | Antibodies, Monoclonal, Humanized - therapeutic use | Busulfan - therapeutic use | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Immunotoxins - therapeutic use | Adolescent | Survival Analysis | Graft vs Host Disease - prevention & control | Aminoglycosides - therapeutic use | Index Medicus
Journal Article
Journal Article
Journal Article